Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Effect of olprinone, a phosphodiesterase III inhibitor, on arterial wall distensibility: Differentiation between aorta and common carotid artery

  • 42 Accesses

  • 5 Citations


Although the effects of phosphodiesterase III (PDE III) inhibitors as vasorelaxants have been well documented, there are only few data on the wall response of different arteries. We evaluated the arteryspecific effect of olprinone (OP), one of the PDE III inhibitors, on the major branches of human arteries and peripheral circulation. In 14 healthy subjects (average age: 57.5 ± 21.2 years), systolic and diastolic diameters (D s andD d, respectively) and the time velocity integral (VI) of flow velocity patterns were measured by M-mode and Doppler echocardiography in the carotid artery (CA), the ascending aorta (asAo), the abdominal aorta (abAo), and the left ventricular outflow tract. Blood pressure (BP) was simultaneously measured using a cuff sphygmomanometer. Measurements were taken before and 20min after a bolus injection of OP (0.2µg/kg). Distensibility (D sD d), stiffness parameter β (ln(systolic BP/diastolic BP)/(D s/D d − 1)), cardiac output (CO: (Flow Area) × VI × HR at left ventricular outflow), selective flow volume (FV: (Flow Area) × VI × HR at CA or abAo), and vascular resistance (VR: mean BP/(CO or FV)) were then calculated. The distensibility increased significantly after OP administration (P = 0.0015), but that of the asAo or abAo did not change. Although there was a significant increase in CO (P = 0.001) and a significant decrease in systemic VR (P = 0.001) following OP administration, the FV and VR of both CA and abAo did not change significantly. The selectiveness of the effect of OP was demonstrated in terms of the CA wall distensibility. This was thought to be attributable to the differences in the structural components or the reactivity of smooth muscle cells to OP.

This is a preview of subscription content, log in to check access.


  1. 1.

    Takaoka H, Takeuchi M, Okada M, Hayashi Y, Mori M, Hata K, Yokoyama M (1993) Comparsion of the effects on arterial-ventricular coupling between phosphodiesterase inhibitor and dobutamine in the diseased human heart. J Am Coll Cardiol 22:598–606

  2. 2.

    Murakami R, Sano K, Murakami Y, Shimada T, Morioka S (1995) Effects of intracoronary infusion of an inotropic agent, E-1020 (loprinone hydrochroride), on cardiac function: evaluation of left ventricular contractile performance using the end-systolic pressure-volume relationship. Int J Cardiol 51:57–63

  3. 3.

    Monrad ES, Baim DS, Smith HS, Lanoue AS, Braunwald E, Grossman W (1985) Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure. Circulation 71:972–979

  4. 4.

    Silver PJ (1989) Biochemical aspects of inhibition of cardiovascular low (Km) cyclic adenosine monophosphate phosphodiesterase. Am J Cardiol 63(suppl):2–8

  5. 5.

    Drummond GI, Severson DL (1979) Cyclic nucleotides and cardiac function. Circ Res 44:145–153

  6. 6.

    Tanio H, Kumada T, Hayashi M, Nakamura Y, Kawai C (1991) Hemodynamic efficacy of E-1020 in comparison with dopamine on acute mitral regurgitation in anesthetized dogs. Jpn Circ J 55:1068–1076

  7. 7.

    Miyahara M, Ito M, Itoh H, Shiraishi T, Isaka I, Konishi T, Nakano T (1995) Isoenzymes of cyclic nucleotide phosphodiesterase in the human aorta: characterization and the effects of E4021. Eur J Pharmacol 284:25–33

  8. 8.

    Ludmer PL, Wright RF, Arnold MO, Ganz P, Braunwald E, Colucci WS (1986) Separation of the direct myocardial and vasodilator actions of milrinone administered by an intracoronary infusion technique. Circulation 73:130–137

  9. 9.

    Hiromoto M, Toma Y, Tomochika Y, Umemoto S, Matsuzaki M (1996) Echographical assessment of the early stage of experimental atherosclerosis of the descending aorta in rabbits. Jpn Circ J 60:691–698

  10. 10.

    Powell JT, Adamson J, MacSweenery STR, Greenhalgh RM, Humpries SE, Henney A (1991) Genetic variants of collagen III and abdominal aortic aneurysm. Eur J Vasc Surg 5:145–148

  11. 11.

    Takahashi T, Tanaka N, Tomochika Y, Wasaki Y, Tone T, Shimazu H, Matsuzaki T, Matsuzaki M (1994) Effects of nifidipine on mechanical properties of the normal and atherosclerotic descending aorta assessed by transesophageal echocardiography. Am J Cardiol 74:1047–1051

  12. 12.

    Safer ME (1996) Carotid artery stiffness with applications to cardiovascular pharmacology. Gen Pharmacol 27:1293–1302

  13. 13.

    Simons PCG, Algra A, Bots ML, Grobbee DE, Graaf Y (1999) Common carotid intima-media thickness and arterial stiffness. Indicators of cardiovascular risk in high-risk patients. The SMART study (second manifestations of arterial disease). Circulation 100:951–957

  14. 14.

    Hayashi K, Handa H, Nagasawa S, Okumura A, Moritake K (1980) Stiffness and elastic behavior of human intracranial and extracranial arteries. J Biomech 13:175–184

  15. 15.

    Kawasaki T, Sasayama S, Yagi S, Asakawa T, Hirai T (1987) Noninvasive assessment of the age related changes in stiffness of major branches of the human arteries. Cardiovasc Res 21:678–687

  16. 16.

    Ahlgren ÅR, Hansen F, Sonesson B, Lanne T (1997) Stiffness and diameter or the common carotid artery and abdominal aorta in women. Ultrasound Med Biol 23:983–988

  17. 17.

    Wada T, Fujishiro K, Fukumoto T, Yamazaki S (1997) Relationship between ultrasound assessment of arterial wall properties and blood pressure. Angiology 48:893–900

  18. 18.

    Hickler RB (1990) Aortic and large artery stiffness: current methodology and clinical correlation. Clin Cardiol 13:317–322

  19. 19.

    Imura T, Yamamoto K, Satoh T, Kanamori K, Mikami T, Yasuda H (1990) In vivo viscoelastic behavior in the human aorta. Circ Res 66:1413–1419

  20. 20.

    O'Rourke M (1990) Arterial stiffness, systolic blood pressure, and logical treatment of arterial hypertension. Hypertension 15:339–347

  21. 21.

    Barenbrock M, Spieker C, Witta J, Evers S, Hoeks APG, Rahn KH, Zidek W (1996) Reduced distensibility of the common carotid artery in patients treated with ergotamine. Hypertension 28:115–119

  22. 22.

    Safar ME, Simon AC, Levenson JA, Cazor JL (1983) Hemodynamic effects of diltiazem in hypertension. Circ Res 52(suppl I):I169-I173

  23. 23.

    Barenbrock M, Spieker C, Hoeks APG, Zidek W, Rahn KH (1994) Effect of lisinopril and metoprolol on arterial distensibility. Hypertension 23(suppl I):I161-I163

  24. 24.

    Dobrin PB, Rovick AA (1969) Influence of vascular smooth muscle on contractile mechanics and elasticity of arteries. Am J Physiol 217:1644–1651

  25. 25.

    Eckly-Michel A, Martin V, Lugnier C (1997). Involvement of cyclic nucleotide-dependent protein inases in cyclic AMP-mediated vasorelaxation. Br J Pharmacol 122:158–164

  26. 26.

    Ohoka M, Honda M, Morioka S, Ishikawa S, Nakayama K, Yamori Y, Moriyama K (1990) Effects of E-1020, a new cyclic AMP-specific phosphodiesterase inhibitor, on cyclic AMP and cytosolic free calcium of cultured vascular smooth muscle cells. Jpn Circ J 54:679–687

  27. 27.

    Itoh H, Kusagawa M, Shimomura A, Suga T, Ito M, Konishi T, Nakano T (1991) Ca2+-dependent and Ca2+-independent vasorelaxation induced by cardiotonic phosphodiesterase inhibitors. Eur J Pharmacol 240:57–66

  28. 28.

    Fujimoto S, Ohashi M, Hiramoto A, Inoue Y, Nagai K, Shiokawa H, Itoh T (1998) Vasorelaxant effect of olprinone, an inhibitor of phosphodiesterase 3, on mesenteric small artery and vein of rabbits. Eur J Pharmacol 353:239–246

  29. 29.

    Fischer GM, Llaurado JG (1996) Collagen and elastin content in canine arteries selected from functionally different vascular beds. Circ Res 19:394–399

  30. 30.

    Harris AL, Grant AM, Siliver PJ, Evans DB, Alousi AA (1989) Differential vasorelaxant effects of milrinone and amrinone on contractile response of canine coronary, cerebral, and renal arteries. J Cardiovasc Pharmacol 13:238–244

  31. 31.

    Kaneko K, Tadano K, Nakajima K, Yuzuriha T, Motoji N, Kawai N, Hasegawa S, Shigematsu A (1994) Studies of the metabolism fate of loprinone hydrochloride (3): blood level, distribution, metabolism, excretion after a single intravenous administration to dogs (in Japanese). Yakubutsu Dotai 9:171–183

  32. 32.

    Kelly R, Hayward C, Avolio A, O'Rourke M (1989) Noninvasive determination of age-related changes in the human arterial pulse. Circulation 80:1652–1659

Download references

Author information

Correspondence to Katsufumi Mizushige.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Seki, M., Mizushige, K., Ueda, T. et al. Effect of olprinone, a phosphodiesterase III inhibitor, on arterial wall distensibility: Differentiation between aorta and common carotid artery. Heart Vessels 14, 224–231 (1999).

Download citation

Key words

  • Phosphodiesterase III inhibitor
  • Olprinone
  • Vascular elasticity
  • Stiffness parameter β
  • Echocardiography